Journal article
Cilostazol for Secondary Stroke Prevention
Abstract
Cilostazol is a PDE3 (phosphodiesterase III) inhibitor with a long track record of safety that is Food and Drug Administration and European Medicines Agency approved for the treatment of claudication in patients with peripheral arterial disease. In addition, cilostazol has been approved for secondary stroke prevention in several Asian countries based on trials that have demonstrated a reduction in stroke recurrence among patients with …
Authors
de Havenon A; Sheth KN; Madsen TE; Johnston KC; Turan TN; Toyoda K; Elm JJ; Wardlaw JM; Johnston SC; Williams OA
Journal
Stroke, Vol. 52, No. 10, pp. e635–e645
Publisher
Wolters Kluwer
Publication Date
October 2021
DOI
10.1161/strokeaha.121.035002
ISSN
0039-2499